BIOLOGÍA MOLECULAR Y CELULAR EN HEMOPATÍAS
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (47)
2022
-
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Blood cancer journal, Vol. 12, Núm. 4, pp. 68
-
A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper
Clinical and Translational Oncology, Vol. 24, Núm. 6, pp. 968-980
-
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients
Annals of Hematology, Vol. 101, Núm. 9, pp. 2053-2067
-
Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19
Blood Advances
-
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550
2021
-
Impact of the COVID-19 pandemic on the care of cancer patients in Spain
ESMO open, Vol. 6, Núm. 3, pp. 100157
2020
-
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols
European Journal of Haematology, Vol. 105, Núm. 2, pp. 138-147
-
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial
Blood Advances, Vol. 4, Núm. 23, pp. 6009-6018
2019
-
Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations
Revista Espanola de Cardiologia, Vol. 72, Núm. 9, pp. 749-759
2018
-
A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
Annals of Hematology, Vol. 97, Núm. 5, pp. 763-772
-
CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis
PLoS ONE, Vol. 13, Núm. 6
-
Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia (Annals of Hematology, (2018), 10.1007/s00277-018-3229-5)
Annals of Hematology
-
Focal adhesion genes refine the intermediate-risk cytogenetic classification of acute myeloid leukemia
Cancers, Vol. 10, Núm. 11
-
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
PLoS ONE, Vol. 13, Núm. 9
2017
-
NEDD 9 an independent good prognostic factor in intermediaterisk acute myeloid leukemia patients
Oncotarget, Vol. 8, Núm. 44, pp. 76003-76014
2016
-
A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia
Hematological Oncology, Vol. 34, Núm. 2, pp. 84-92
-
Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy
British Journal of Haematology, Vol. 174, Núm. 6, pp. 859-867
-
UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation
Bone Marrow Transplantation, Vol. 51, Núm. 1, pp. 79-82
2015
-
CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia
Haematologica
-
CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival
Journal of Pathology, Vol. 235, Núm. 3, pp. 445-455